Examining The Antibody-Drug Conjugate Pipeline
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches.